Amedeo's Top 20

Amedeo Smart

Independent Medical Education

22 July 2024

Multidisciplinary Journal Club

  1. Simon TG, Singer DE, Zhang Y, Mastrorilli JM, et al.
    Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
    Ann Intern Med 2024.

  1. Njenga C, Ramanuj PP, de Magalhaes FJC, Pincus HA, et al.
    New and emerging treatments for major depressive disorder.
    BMJ 2024;386:e073823.

  2. Karlqvist S, Sachs MC, Eriksson C, Cao Y, et al.
    Comparative risk of serious infection with vedolizumab vs anti-TNF in inflammatory bowel disease: results from nationwide Swedish registers.
    Am J Gastroenterol 2024.

  3. Liu J, Li Y, Ge J, Yan X, et al.
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet 2024.

  4. Prakash Babu S, Ezhumalai K, Raghupathy K, Karoly M, et al.
    Factors associated with unfavourable treatment outcomes among persons with Pulmonary Tuberculosis: a multicentric prospective cohort study from India.
    Clin Infect Dis 2024.

  1. Xie P, Shen L, Peng R, Wang Y, et al.
    Effects of low-dose methotrexate with MMI in patients with Graves' disease: results of a randomized clinical trial.
    J Clin Endocrinol Metab 2024.

  2. Nielsen FM, Klitgaard TL, Bruun NH, Moller MH, et al.
    Lower or higher oxygenation targets in the intensive care unit: an individual patient data meta-analysis.
    Intensive Care Med 2024.

  3. Holper S, Loveland P, Churilov L, Italiano D, et al.
    Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Neurology 2024;103:e209537.

  4. Anastasilakis AD, Polyzos SA, Makras P, Savvidis M, et al.
    The comparative effect of teriparatide and denosumab on activins, follistatins and inhibins in women with postmenopausal osteoporosis.
    J Bone Miner Res 2024.

  5. Kochhar GS, Khataniar H, Jairath V, Farraye FA, et al.
    Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A U.S. Propensity-Matched Cohort Study.
    Am J Gastroenterol 2024.

  1. Jing R, Wu N, Wu Y, Zhang Q, et al.
    Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.
    J Clin Endocrinol Metab 2024.

  2. Zanghi A, Borriello G, Bonavita S, Fantozzi R, et al.
    Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    J Neurol 2024;271:4495-4502.

  3. Kramer CK, Retnakaran M, Viana LV.
    Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.
    J Clin Endocrinol Metab 2024;109:e1634-e1641.

  4. Switalla KM, Boughey JC, Dimitroff K, Yau C, et al.
    Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    Ann Surg Oncol 2024.

  5. Pan K, Nelson RA, Chlebowski RT, Piela R, et al.
    Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women's Health Initiative.
    Breast Cancer Res Treat 2024;207:65-79.

  1. Paludan-Muller C, Vad OB, Stampe NK, Diederichsen SZ, et al.
    Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality.
    Eur Heart J 2024.

  2. Jennerich AL.
    An Approach to Caring for Patients and Family of Patients Dying in the ICU.
    Chest 2024;166:127-135.

  3. Grigg S, Minson A, Prins E, Dickinson MJ, et al.
    Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
    Br J Haematol 2024;205:122-126.

  4. Carlo-Stella C.
    Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
    Br J Haematol 2024;205:17-19.

  5. Wenzel M, Wagner N, Hoeh B, Siech C, et al.
    Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.
    Prostate 2024.


more..

Privacy Policy